-
1.发明申请POLYPEPTIDES THAT BIND TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS 审中-公开金属蛋白酶类型三（TIMP-3）的组合抑制剂的多肽，组合物和方法
公开(公告)号：WO2011014671A1
公开(公告)日：2011-02-03
申请号：PCT/US2010/043737
申请日：2010-07-29
Applicant: AMGEN INC. , BLACK, Roy, A. , LI, Peng , SILVERMAN, Joshua , KING, Chadwick, T.
Inventor： BLACK, Roy, A. , LI, Peng , SILVERMAN, Joshua , KING, Chadwick, T.
CPC classification number: C07K14/81 , A61K38/00 , A61K38/57 , C07K7/08 , C07K14/8146 , C07K16/38 , C07K2317/21 , C07K2317/76
Abstract: The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.
Abstract translation: 本发明涉及TIMP-3结合组合物，制备这种组合物的方法，以及使用这些组合物的方法，包括在各种条件的治疗中。
-
公开(公告)号：WO2010075238A1
公开(公告)日：2010-07-01
申请号：PCT/US2009/068858
申请日：2009-12-18
Applicant: AMGEN INC. , BOONE, Thomas C. , BRANKOW, David W. , GEGG, JR., Colin V. , HU, Shaw-Fen Sylvia , KING, Chadwick T. , LU, Hsieng Sen , SHI, Licheng , XU, Cen
Inventor： BOONE, Thomas C. , BRANKOW, David W. , GEGG, JR., Colin V. , HU, Shaw-Fen Sylvia , KING, Chadwick T. , LU, Hsieng Sen , SHI, Licheng , XU, Cen
CPC classification number: C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
Abstract translation: 提供了结合人CGRP受体（CGRP R）的抗原结合蛋白。 还提供编码抗原结合蛋白，载体和编码抗原结合蛋白的核酸的核酸。 抗原结合蛋白可以抑制CGRP R与CGRP的结合，并且可用于多种CGRP R相关疾病，包括治疗和/或预防偏头痛。
-
3.发明申请
公开(公告)号：WO2005016111A3
公开(公告)日：2006-05-04
申请号：PCT/US0325161
申请日：2003-08-08
Applicant: ROSKOS LORIN , FOLTZ IAN , KING CHADWICK T , ABGENIX INC
Inventor： ROSKOS LORIN , FOLTZ IAN , KING CHADWICK T
IPC: A61K39/395 , C07K16/26
CPC classification number: C07K16/26 , A01K2217/075 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/76 , C07K2317/92
Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.
Abstract translation: 本文描述的本发明的实施方案涉及针对抗原甲状旁腺激素（PTH）的抗体和此类抗体的用途。 特别地，在一些实施方案中，提供针对抗原PTH的完全人单克隆抗体。 在另外的实施方案中，编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。
-
4.发明申请ANTIBODIES DIRECTED TO PARATHYROID HORMONE (PTH) AND USES THEREOF 审中-公开针对PARATHYROID HORMONE（PTH）的抗体及其用途
公开(公告)号：WO2005016111A2
公开(公告)日：2005-02-24
申请号：PCT/US2003/025161
申请日：2003-08-08
Applicant: ABGENIX, INC. , ROSKOS, Lorin , FOLTZ, Ian , KING, Chadwick, T.
Inventor： ROSKOS, Lorin , FOLTZ, Ian , KING, Chadwick, T.
IPC: A61B
CPC classification number: C07K16/26 , A01K2217/075 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/76 , C07K2317/92
Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.
Abstract translation: 本文描述的本发明的实施方案涉及针对抗原甲状旁腺激素（PTH）的抗体和此类抗体的用途。 特别地，在一些实施方案中，提供针对抗原PTH的完全人单克隆抗体。 在另外的实施方案中，编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于横跨框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。
-
Patent Agency Ranking5.发明申请ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF 审中-公开抗体生长因子受体的遗传突变体的抗体及其用途
公开(公告)号：WO2005012479A3
公开(公告)日：2006-10-12
申请号：PCT/US2004020564
申请日：2004-06-25
Applicant: ABGENIX INC , WEBER RICHARD , FENG XIAO , FOORD ORIT , GREEN LARRY , GUDAS JEAN , KEYT BRUCE , LIU YING , RATHANASWAMI PALANI , RAYA ROBERT , YANG XIAO DONG , CORVALAN JOSE , FOLTZ IAN , JIA XIAO-CHI , KANG JASPAL , KING CHADWICK T , KLAKAMP SCOTT L , SU QIAOJUAN JANE
Inventor： WEBER RICHARD , FENG XIAO , FOORD ORIT , GREEN LARRY , GUDAS JEAN , KEYT BRUCE , LIU YING , RATHANASWAMI PALANI , RAYA ROBERT , YANG XIAO DONG , CORVALAN JOSE , FOLTZ IAN , JIA XIAO-CHI , KANG JASPAL , KING CHADWICK T , KLAKAMP SCOTT L , SU QIAOJUAN JANE
IPC: C07K16/28 , A61K39/395 , A61K39/44 , A61K47/48 , C07H21/04 , C07K14/71 , C07K16/22 , C07K16/42 , C07K17/00 , C12N20060101 , C12N5/06 , C12N5/12 , C12P21/08 , G01N33/53 , G01N33/552 , G01N33/577
CPC classification number: C07K16/30 , A61K47/6803 , A61K47/6849 , A61K47/6897 , A61K2039/505 , B82Y5/00 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/77 , C07K2317/92 , Y10S435/81
Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体的缺失突变体的抗体，特别涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体，特别是EGFRvIII的缺失突变体的人单克隆抗体。 还提供了这种抗体的诊断和治疗制剂及其免疫偶联物。
-
6.发明申请
公开(公告)号：WO2005010151A3
公开(公告)日：2005-02-03
申请号：PCT/US2004/020295
申请日：2004-06-25
Applicant: ABGENIX, INC , WEBER, Richard , FENG, Xiao , FOORD, Orit , GREEN, Larry , GUDAS, Jean , KEYT, Bruce , LIU, Ying , RATHANASWAMI, Palani , RAYA, Robert , YANG, Xiao, Dong , CORVALAN, Jose , FOLTZ, Ian , JIA, Xiao-Chi , KANG, Jaspal , KING, Chadwick, T. , KLAKAMP, Scott, L. , SU, Qiaojuan, Jane
Inventor： WEBER, Richard , FENG, Xiao , FOORD, Orit , GREEN, Larry , GUDAS, Jean , KEYT, Bruce , LIU, Ying , RATHANASWAMI, Palani , RAYA, Robert , YANG, Xiao, Dong , CORVALAN, Jose , FOLTZ, Ian , JIA, Xiao-Chi , KANG, Jaspal , KING, Chadwick, T. , KLAKAMP, Scott, L. , SU, Qiaojuan, Jane
IPC: A61K39/395
Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
-
7.发明申请
公开(公告)号：WO2005016111A9
公开(公告)日：2005-05-19
申请号：PCT/US0325161
申请日：2003-08-08
Applicant: ABGENIX INC , ROSKOS LORIN , FOLTZ IAN , KING CHADWICK T
Inventor： ROSKOS LORIN , FOLTZ IAN , KING CHADWICK T
IPC: A61K39/395 , C07K16/26 , A61B
CPC classification number: C07K16/26 , A01K2217/075 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/76 , C07K2317/92
Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.
Abstract translation: 本文描述的本发明的实施方案涉及针对抗原甲状旁腺激素（PTH）的抗体和此类抗体的用途。 具体而言，在一些实施方案中，提供了针对抗原PTH的完全人类单克隆抗体。 在进一步的实施方案中，编码核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。
-
8.发明申请ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF 审中-公开抗体指导表皮生长因子受体的缺失突变及其应用
公开(公告)号：WO2005012479A2
公开(公告)日：2005-02-10
申请号：PCT/US2004/020564
申请日：2004-06-25
Applicant: ABGENIX, INC , WEBER, Richard , FENG, Xiao , FOORD, Orit , GREEN, Larry , GUDAS, Jean , KEYT, Bruce , LIU, Ying , RATHANASWAMI, Palani , RAYA, Robert , YANG, Xiao, Dong , CORVALAN, Jose , FOLTZ, Ian , JIA, Xiao-Chi , KANG, Jaspal , KING, Chadwick, T. , KLAKAMP, Scott, L. , SU, Qiaojuan, Jane
Inventor： WEBER, Richard , FENG, Xiao , FOORD, Orit , GREEN, Larry , GUDAS, Jean , KEYT, Bruce , LIU, Ying , RATHANASWAMI, Palani , RAYA, Robert , YANG, Xiao, Dong , CORVALAN, Jose , FOLTZ, Ian , JIA, Xiao-Chi , KANG, Jaspal , KING, Chadwick, T. , KLAKAMP, Scott, L. , SU, Qiaojuan, Jane
IPC: C12N
CPC classification number: C07K16/30 , A61K47/6803 , A61K47/6849 , A61K47/6897 , A61K2039/505 , B82Y5/00 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/77 , C07K2317/92 , Y10S435/81
Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫偶联物。
-
9.发明申请ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF 审中-公开抗体指导表皮生长因子受体的缺失突变及其应用
公开(公告)号：WO2005010151A2
公开(公告)日：2005-02-03
申请号：PCT/US2004020295
申请日：2004-06-25
Applicant: ABGENIX INC , WEBER RICHARD , FENG XIAO , FOORD ORIT , GREEN LARRY , GUDAS JEAN , KEYT BRUCE , LIU YING , RATHANASWAMI PALANI , RAYA ROBERT , YANG XIAO DONG , CORVALAN JOSE , FOLTZ IAN , JIA XIAO-CHI , KANG JASPAL , KING CHADWICK T , KLAKAMP SCOTT L , SU QIAOJUAN JANE
Inventor： WEBER RICHARD , FENG XIAO , FOORD ORIT , GREEN LARRY , GUDAS JEAN , KEYT BRUCE , LIU YING , RATHANASWAMI PALANI , RAYA ROBERT , YANG XIAO DONG , CORVALAN JOSE , FOLTZ IAN , JIA XIAO-CHI , KANG JASPAL , KING CHADWICK T , KLAKAMP SCOTT L , SU QIAOJUAN JANE
IPC: A61K39/395 , A61K47/48 , C07K16/22 , C07K16/28 , C07K17/00 , C12N20060101 , C12N5/06 , G01N33/53 , C12N
CPC classification number: C07K16/30 , A61K47/6803 , A61K47/6849 , A61K47/6897 , A61K2039/505 , B82Y5/00 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/77 , C07K2317/92 , Y10S435/81
Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫缀合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.022 seconds)
